Inhibition of antigen-presenting cell function by alendronate in vitro,
Bisphosphonates are potent inhibitors of bone resorption in vivo and are emerging as important and widely used drugs for the treatment of a variety of abnormal bone resorptive processes.
Fagnoni F. +6 more
core
Synthesis of a Series of Heterocyclic N-Substituted Derivatives of Alendronic Acid and Their Preliminary Biological Evaluation. [PDF]
Nasulewicz-Goldeman A +3 more
europepmc +1 more source
Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study. [PDF]
Chen M +10 more
europepmc +1 more source
Response to "Interpreting bone turnover responses and treatment persistence with once-weekly teriparatide". [PDF]
Gu J, Zhao Q, Zhang X, Zhang Z.
europepmc +1 more source
Clinical and Radiological Outcomes of Oral Bisphosphonate Therapy Combined with Conservative Treatment in Subchondral Bone Marrow Edema of the Knee: A Retrospective Cohort Study. [PDF]
Yurdakul G +7 more
europepmc +1 more source
Gut Microbiota and SCFA Changes After Alendronate-Calcitriol Therapy in Postmenopausal Osteoporosis. [PDF]
Shen F, Hu L, Xin C, Du F, Zhang S.
europepmc +1 more source
Bisphosphonate therapy for thalassemia-related bone disorders in children and young adults: a systematic review. [PDF]
Mangkuliguna G +2 more
europepmc +1 more source
Effects of different anti-osteoporosis medications on re-fracture risk, bone mineral density, and functional recovery following hip fragility fracture surgery: a systematic review and network meta-analysis. [PDF]
Tian J +7 more
europepmc +1 more source
24-month real-world persistence and compliance of denosumab versus alendronate among postmenopausal women with osteoporosis in Australia, Taiwan, South Korea, Hong Kong, and Singapore. [PDF]
Lau TC +10 more
europepmc +1 more source
Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report. [PDF]
Olsson SB, Ehinger M.
europepmc +1 more source

